跳至主要内容
临床试验/NCT04764305
NCT04764305招募中不适用

Liver Disease, Myocardial Fibrosis and Collaterals in the Adult Fontan Patient - a Metabolomics and Proteomics Approach

Medical University Innsbruck1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2022年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
300
试验地点
1
主要终点
Number of participants

研究概览

简要总结

Out objective is to identify the mechanisms that promote hepatic and myocardial fibrosis, and collateral vessel formation in patients with complex congenital heart disease and Fontan circulation.

详细描述

In their prior works the investigators could show that there is evidence of a proinflammatory condition in a certain subgroup of patients with complex congenital heart disease and a so called Fontan circulation. Those patients are also prone to develop hepatic and myocardial fibrosis as well as to reveal collateral vessel formation. The investigators' hypothesis is that this pro-inflammatory condition is not only reflecting pre-stages of one or more of those 3 issues, but that this is also a main driving mechanism to develop and hepatic or myocardial fibrosis and collateral vessels.

The objective of the here proposed study thus is to identify the mechanisms that promote hepatic and myocardial fibrosis, and collateral vessel formation, and thus provide insight into the determination of those Fontan patients that tend to develop those conditions. The investigators attempt to link the issues of hepatic and myocardial fibrosis and collateral vessel formation by directing our focus on the phospholipid, amino acid and bile acid metabolism and on cell surface markers, cytokines, and chemokines as surrogates for proinflammatory, profibrotic and proangiogenic conditions.

This study would thereby allow for a deeper insight into Fontan pathophysiology and sequelae and might provide first steps towards the identification of possible diagnostic or eventually therapeutic targets.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • written informed consent of participants
  • age at testing of ≥18 years
  • 8 h fasting before blood sampling
  • Fontan circulation (patients)
  • biventricular heart without structural or functional abnormality (controls)

排除标准

  • Protein losing enteropathy (PLE) (patients are defined as "PLE positive" if there is/are serum protein <5g/dL and serum albumin <3g/dL (duration for more than 3 months and exclusion of other causes for hypoproteinemia) and documented enteric protein loss: faecal alpha-1-antitrypsin ≥400 µg/g
  • medication directly affecting metabolic state, such as cholesterol-lowering agents, or haemodynamic state, such as beta-blockers or sildenafil, with the exception of angiotensin converting enzyme inhibitors, diuretics, and anticoagulants
  • atrial or ventricular arrhythmia
  • coronary artery disease (history of myocardial infarction, myocardial revascularisation, percutaneous coronary intervention, or coronary artery bypass surgery)
  • any metabolic disease, such as diabetes mellitus
  • malignancy
  • obesity (body mass index (BMI) >25 kg/m2)
  • underweight (BMI < 18 kg/m2)
  • renal disease
  • inflammatory disease such as acute or chronic infection
  • myeloproliferative disorder
  • pregnancy or lactation
  • malnourishment
  • mental handicap not allowing valid consent to participation in the study or CMR
  • need of sedation or general anesthesia for CMR
  • typical contraindications for performing CMR such as metal-containing mechanical or electronic implants
  • claustrophobia

结局指标

主要结局

Number of participants

时间窗: July 2021-December 2023

When aspired number of participants is reached

次要结局

未报告次要终点

研究者

发起方
Medical University Innsbruck
申办方类型
Other
责任方
Principal Investigator
主要研究者

OÄ Dr. Miriam Michel

Principal Investigator

Medical University Innsbruck

研究点 (1)

Loading locations...

相似试验